EMBC vs NVCR

For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.

3% revenue growth year-over-year, versus -3. 8% for Embecta Corp. (EMBC). Embecta Corp. (EMBC) offers the better valuation at 2. 2x trailing P/E (1. 3x forward), making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Embecta Corp.

(EMBC) delivered a total return of -87. 6%, compared to -91. 5% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: NVCR returned +31. 0% versus EMBC's -87. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Embecta Corp.

(EMBC) is the lower-risk stock at 1. 31β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 68% more volatile than EMBC relative to the S&P 500.

By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.

3% versus -3. 8% for Embecta Corp. (EMBC). On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21. 8% year-over-year, compared to 20. 9% for Embecta Corp.. Over a 3-year CAGR, NVCR leads at 6. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Embecta Corp.

(EMBC) is the more profitable company, earning 8. 8% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 8. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EMBC leads at 30. 5% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for EMBC: 237.

1% to $12. 00.

In this comparison, EMBC (16.

7% yield) pays a dividend. NVCR does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Embecta Corp.

(EMBC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (16. 7% yield). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EMBC: -87. 6%, NVCR: +31. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: EMBC is a small-cap deep-value stock; NVCR is a small-cap quality compounder stock. EMBC pays a dividend while NVCR does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.